CONMED Q1 2026: GAAP EPS $0.45, adjusted EPS $0.89; raises FY organic revenue growth guidance

CONMED Corp

Sales $317.0M (-1.3% YoY); domestic -5.8%, international +4.7% as reported.
GAAP EPS $0.45 vs $0.19 YoY; adjusted EPS $0.89 vs $0.95.
FY 2026 organic constant currency revenue growth guidance raised to 5.0-6.5% from 4.5-6.0%.
Reported revenue guidance raised to $1.350-1.375B; adjusted EPS reaffirmed $4.30-$4.45.
GI product exit impacted sales by $15.5M; company focusing on higher-growth areas.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

CONMED Corp reported FY 2026 results: EPS $4.30 to $4.45. Guidance reaffirmed.

Period: FY 2026
EPS: $4.30 to $4.45
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

The Company now expects year-over-year organic constant currency revenue growth, which excludes gastroenterology product sales, of approximately 5.0% to 6.5% compared to the prior guidance range of 4.5% to 6.0%. Full-year 2026 reported revenue is now expected to be in the range of $1.350 billion to $1.375 billion, compared to prior guidance of $1.345 billion to $1.375 billion.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

CONMED Corp reported FY 2026 results: EPS $4.30 to $4.45. Guidance reaffirmed.

Period: FY 2026
EPS: $4.30 to $4.45
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

The Company continues to expect full-year adjusted diluted net earnings per share (2) in the range of $4.30 to $4.45.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

CONMED Corp reported Q1 2026 results: EPS $0.89.

Period: Q1 2026
EPS: $0.89
Result: reported results

Exact text from the filing

Adjusted diluted net earnings per share (1) were $0.89, compared to adjusted diluted net earnings per share of $0.95 in the first quarter of 2025.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

CONMED Corp filing history →

Source: SEC EDGAR

accession 0000816956-26-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.